IFN- efficacy reduced by NAbs, but do they last?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1505, 2005-01, pp. : 17-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Do Older Adults Using NSAIDs Have a Reduced Risk of Colorectal Cancer?

By Hoffmeister Michael Chang-Claude Jenny Brenner Hermann

Drugs & Aging, Vol. 23, Iss. 6, 2006-01 ,pp. : 513-523

Adis International

Access to resources Recommend Favorite

The safety and efficacy of apixaban: where do we stand in 2013?

By de Souza Brito Flavio Lopes Renato D Alexander John H

Expert Opinion on Drug Safety, Vol. 12, Iss. 4, 2013-07 ,pp. : 559-567

Informa Healthcare

Access to resources Recommend Favorite

Can IFN- be used in Guillain-Barré syndrome?

Inpharma, Vol. 1, Iss. 1252, 2000-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

IFN- : a molecular target for bone diseases?

Inpharma, Vol. 1, Iss. 1337, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

IFN- cost effective for MS after all?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 272, 2000-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite